Backgrounds and aims Hypertrophic cardiomyopathy (HCM) causes cardiac death through
both sudden cardiac death (SCD) and death due to heart failure (HF). Although adipokines …

Background Adipokines mediate cardiometabolic risk associated with obesity but their role
in the pathogenesis of obesity‐associated heart failure remains uncertain. We investigated …

Aims Nutritional status has been related to clinical outcomes in patients with cardiovascular
diseases. The prognostic impact of poor nutritional status in hypertrophic cardiomyopathy …

Objective To analyse the characteristics and mortality of hypertrophic cardiomyopathy
(HCM) patients with different body compositions. Methods In this study, 530 consecutive …

Background: Only a subset of patients with hypertrophic cardiomyopathy (HCM) develop
adverse cardiac events–eg, end-stage heart failure, cardiovascular death. Current risk …

Background Previous studies have shown the importance of energy deficiency and
malfunctioning mitochondria in the pathophysiology of hypertrophic cardiomyopathy (HCM) …

Background Previous studies have shown that the clinical expression of hypertrophic
cardiomyopathy (HCM) can be determined by obesity and metabolic syndrome. The present …

Hypertrophic cardiomyopathy (HCM) is a heart disease characterized by hypertrophy of the
left ventricular myocardium and is most often caused by mutations in sarcomere genes. The …

Eur J Clin Invest 2012; 42 (10): 1079–1086 Abstract Objectives The goal of this study was
designed to assess prognostic values of simultaneous measurement of adipocytokines in …

Aims We evaluated the impact of echocardiographic epicardial adipose tissue (EAT) on
cardiovascular haemodynamics, metabolic profile and prognosis in heart failure (HF) using …